Incannex Healthcare develops combination drugs for sleep apnea and anxiety, based in Norwest, New South Wales. IXHL reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Jun 8 | Alliance Global Partners | Initiated | Buy |
Seasonality
How IXHL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in IXHL in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IXHL is in one of them and how their past IXHL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IXHL in an article yet. Here's the latest on the wider market.
About Incannex Healthcare
Incannex Healthcare is a drug development company based in Norwest, New South Wales. It is developing combination medicines taken by mouth, along with a treatment that pairs synthetic psilocybin with psychological therapy. Its main development focus is a treatment for obstructive sleep apnea, and a second program targets generalized anxiety disorder. The company is at the clinical trial stage and aims to give patients treatment options where existing care falls short.
- Headquarters
- Norwest Nsw